IRVINE, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the second quarter of 2011 increased 32% to $1.2 million from $916,000 in the second quarter of 2010. Sequentially, second quarter 2011 total revenues increased 32% from $913,000 in the first quarter of 2011. Diagnostic testing services revenues during the second quarter of 2011, which comprised all of the revenues generated, increased 52% compared to diagnostic test services revenues of $796,000 recognized during the second quarter of 2010. The Company performed a total of 1,201 billable diagnostic tests for 106 customers in the second quarter of 2011, compared to 773 tests for 66 customers in the second quarter of 2010 and 958 tests for 86 customers in the first quarter of 2011. For the six months ended June 30, 2011, total revenues increased by 22% to $2.1 million as compared to $1.7 million for the comparable 2010 period.
